Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Ascendis Pharma A/S
Ascendis Pharma A/S News
Ascendis Pharma A/S Quantitative Score
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S Earnings & Revenue
Ascendis Pharma A/S Financials
Table Compare
Compare ASND metrics with: | |||
|---|---|---|---|
Earnings & Growth | ASND | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ASND | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ASND | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ASND | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Ascendis Pharma A/S Income
Ascendis Pharma A/S Balance Sheet
Ascendis Pharma A/S Cash Flow
Ascendis Pharma A/S Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Ascendis Pharma A/S Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Ascendis Pharma A/S Executives
| Name | Role |
|---|---|
| Ms. Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President & Head of Clinical Development for Oncology |
| Mr. Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer & Member of the Executive Board |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Mr. Mads Bodenhoff | Senior Vice President of Finance & Principal Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board | Female | 1961 | -- |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President & Head of Clinical Development for Oncology | 1974 | -- | |
| Mr. Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer & Member of the Executive Board | Male | 1971 | -- |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | Male | 1961 | -- |
| Mr. Mads Bodenhoff | Senior Vice President of Finance & Principal Accounting Officer | Male | -- |